China Biologic Products, Inc. has been gaining a reputation as one of the leading plasma-based pharmaceutical companies in the People’s Republic of China and has obtained great success operating through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co. and Chongging Dalin Biologic Technologies Co. While the young company has been making strides across the globe, they obtained a major asset to their company with the announcement that they have appointed Dr. Vincent Yi-Wu Xie to become the new Director of Research and Development.

Dr. Xie brings a lot of experience and credibility to the China Biologic team. Dr. Xie is a veteran in the biopharmaceutical industry and has published several papers and articles related to the field of plasma-based research. He holds a number of patents related to his biopharmaceutical research, including research on plasma-derived hyperimmune globulins and alpha-1 proteinase inhibitor, and has received the Guangzhou City Science

...

L&L International Holdings Inc. is headquartered in the United States, but is in the coal business in China. The company is currently operating two profitable coal mines, two clean coal washing facilities, and a wholesale network in the coal-rich Yunnan province in China.

The company is attempting to take advantage of a strong coal market in China. Coal prices have risen sharply in China this year as the government has cracked down on illegal and polluting mines, closing many of them. The closure of these mines has led to decreased supplies of coal and increasing prices for the remaining producers.

The company announced today that it has submitted a new subsidiary application to the GuangZhou City (located about 75 miles north of Hong Kong) government, to expand their operations into this capital of the wealthy Guandong province. The new subsidiary was provisionally named Shining Star Co. Ltd.

L&L

...

Nissan losses lower than expected   The world’s third largest carmaker, Nissan Motor Company (NSANY), posted a modest net loss of 9 cents (¥4.06) per share in the first quarter of fiscal 2009. The loss was largely driven by the slump in global car demand, negative impact of a stronger yen, sharp decline in consumer confidence in all the major markets and product mix deterioration. Reported losses were significantly lower than the Zacks consensus forecast of 80 cents. Cost-cutting efforts, coupled with the government stimulus, helped Nissan curb losses in the quarter. The government of US, Germany, Japan and China are offering consumers credits, tax breaks and subsidies for trading in old cars for new fuel-efficient models. However, we remain concerned about Nissan’s prospects as these government incentives will not be available for much longer. Operating costs shrunk 37% year over year to $25.2 billion ...

The Guangdong-based department store retailer Jusco, a subsidiary of the Japanese retail giant Aeon, has accelerated its expansion in the Chinese market with a new project in Popark, Guangzhou. Popark is jointly developed by Guangzhou City Construction and Development Property and the Hong Kong-headquartered Way Kon Group, and is a business project that will focus on [...]